For handy access to most of the links mentioned below and to download your certificate of attendance, visit AAN.com/FCQuickLinks
WiFi is available throughout the conference meeting rooms.
Some programs will seek input from participants in real time. To participate in audience response, visit AAN.cnf.io
Download the AAN Conferences mobile app at AAN.com/MobileApp and log in with your six-digit AAN ID and password to build your personalized schedule, get notification reminders throughout the conference, see program materials, claim CME, and more. Please note that your schedule in the mobile app will not sync with personalized schedules built in the virtual platform available at AAN.com/VirtualFC
Available online at AAN.com/FCMaterials or within the AAN Conferences mobile app. Use your six-digit AAN ID and password to log in. Please note that availability of materials is at the discretion of the specific speaker. Not all sessions will have materials.
CME hours can be claimed by completing the program evaluation at AAN.com/FCCME or in the AAN Conferences mobile app by November 13, 2022, with Full Registration; or by August 1, 2023, if you added On Demand. Transcripts will be available upon evaluation submission. AAN members can also access their transcript via NeuroTracker™ at AAN.com/NeuroTracker
Mealtimes and locations are noted in the schedule.
A private room for nursing/pumping and/or praying/meditation is available for use during the conference. To use, please check in at the registration desk.
Visit AAN.com/VirtualFC and log in with your six-digit AAN ID and password to view sessions live online. This option works best using Google Chrome on a desktop or tablet. Session recordings will be available approximately 24 hours after their originally scheduled time at the same URL. You can access session recordings through November 13, 2022, with your registration. If you added On Demand to your registration, you’ll have access to session recordings in the Online Learning Center (Learning.AAN.com) from November 14, 2022–August 1, 2023. Want to extend your access? Email aanfcsupport@cmrus.com to add On Demand by November 13, 2022. Please note that your schedule in the virtual platform will not sync with your personalized schedule in the AAN Conferences mobile app.
Learn about the latest advancements in products and services enhancing the lives of neurology patients and their care providers.
Use your Exhibit Hall passport to visit a world of exhibitors and enter drawings to win prizes including Bose Noise Cancelling Headphones and 2023 Annual Meeting Registration.
Join us for the Exhibit Hall Reception on Friday, October 28, from 4:00 p.m.–6:00 p.m., which will offer attendees an opportunity to enjoy refreshments, network with new and known colleagues, and visit exhibits.
APP
15-16
Unless otherwise indicated, programs are available in Las Vegas and online.
Friday, October 28
Octavius 15-16
Friday’s Live from Las Vegas Virtual Kickoff
Leading the Self–Knowing Who You Are and What You Want*
Exhibit Hall Break
Octavius 12-14
Building Service Lanes*
Overcoming Barriers in Management and Leadership*
Epilepsy and Headache*
Neuromuscular Junction Disorders: Myasthenia Gravis, Ocular, and MuSK Myasthenia*
The Intersection of Wellness, Diversity, and Inclusion Octavius 12-14
Neurology Emergencies and Neuro Ethics*
Contemporary Clinical Issues Plenary Session*
Exhibit Hall Lunch
Octavius 12-14
Curbside Consults: Epilepsy Octavius 12-14
Telemedicine*
HR/Staffing*
Business Administrator Networking Session Octavius 15-16
Leading a Team to a Strategic Decision*
Advanced Practice Provider Networking Session Octavius 6
Basic Science: Neuropharma cology 1
Exhibit Hall Reception
Octavius 12-14
Exhibit Hall Break Octavius 12-14
Leading the Change Through Communication–The Impact of Communication on Change*
Neuromuscular Disease and Adolescent/Child Neurology for the Adult Neurologists* Dementia and Multiple Sclerosis*
Neuromyelitis Optica Spectrum Disorders*
Hot Topics in Headache*
Neuro Exam Tips and Tricks Octavius 12-14
Neurology Update en Español
7:30 A.M. 7:45 A.M. 8:00 A.M. 9:30 A.M. 10:00 A.M. 11:30 A.M. 11:45 A.M. 12:45 P.M. 1:00 P.M. 2:30 P.M. 3:00 P.M. 4:00 P.M. 6:00 P.M.
7:30 A.M.
7:45 A.M.
8:00 A.M.
Saturday,
Octavius 15-16
29
Octavius 9-11
Learning Health Care Sytem*
Neuro-ophthalmology and Neurotoxicology*
Octavius 19-21
9:30 A.M. 10:00 A.M. 11:30 A.M. 11:45 A.M. 12:45 P.M. 1:00 P.M. 2:30 P.M.
P.M.
Exhibit Hall Break
Octavius 12-14
Value-based Care*
Neuroscience in the Clinic: Applications of Artificial Intelligence and Machine Learning Tools in Neurology*
Fireside Chat: Thinking of Changing Careers Octavius 12-14
Infectious Disease and Neuro-oncology*
P.M.
Exhibit Hall Lunch Octavius 12-14 Practice and Innovation*
Curbside Consults: Dementia Octavius 12-14
Continuum® Test Your Knowledge: A Multiplechoice Question Review 1*
Basic Science: Neuropharmacology 2
P.M.
Beyond the Bedside: Productivity*
Continuum® Test Your Knowledge: A Multiplechoice Question Review 2*
LGBTQI Health in Neurology*
Hot Topics Plenary Session*
Intervention al Headache Manage ment: Botulinum Toxin, Nerve Blocks, Trigger Point Injections, Surgery, and Neuromodu lation* Octavius 17-18
A.M.
A.M.
Cerebrovascular Disease and
for Relapsing
Northeast Georgia Health System (NGHS) is seeking compassionate Neurology physicians and Advanced Practice Providers (APPs) to join our rapidly growing Neurosciences team. NGHS facilitates quality-based Neurological care for a medically diverse population of over 1.2 million patients spanning 19 counties.
A.M.
with Lambert-Eaton myasthenic syndrome (LEMS)1
FIRDAPSE is a
References:
FIRDAPSE®
FIRDAPSE is a potassium channel blocker indicated for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults.
• The recommended starting dosage is 15 mg to 30 mg daily taken orally in divided doses (3 to 4 times daily)
- Starting dosage is 15 mg daily for patients with renal impairment, hepatic impairment, and in known N-acetyltransferase 2 (NAT2) poor metabolizers
• Dosage can be increased by 5 mg daily every 3 to 4 days
• Dosage is not to exceed a maximum of 80 mg daily
• The maximum single dose is 20 mg
FIRDAPSE is contraindicated in patients with:
• A history of seizures
• Hypersensitivity to amifampridine phosphate or another aminopyridine
FIRDAPSE can cause seizures. Seizures have been observed in patients without a history of seizures taking FIRDAPSE at the recommended doses, at various times after initiation of treatment, at an incidence of approximately 2%. Many of the patients were taking medications or had comorbid medical conditions that may have lowered the seizure threshold. Seizures may be dose-dependent. Consider discontinuation or dose-reduction of FIRDAPSE in patients who have a seizure while on treatment.
FIRDAPSE is contraindicated in patients with a history of seizures.
In clinical trials, hypersensitivity reactions and anaphylaxis associated with FIRDAPSE administration have not been reported. Anaphylaxis has been reported in patients taking another aminopyridine; therefore, it may occur with FIRDAPSE. If anaphylaxis occurs, administration of FIRDAPSE should be discontinued and appropriate therapy initiated.
The following serious adverse reactions are described elsewhere in the labeling:
• Seizures
• Hypersensitivity
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not re ect the rates observed in practice.
In controlled and uncontrolled trials (Study 1 and 2) in patients with LEMS, 63 patients were treated with FIRDAPSE, including 40 patients treated for more than 6 months, and 39 patients treated for more than 12 months. In an expanded access program, 139 patients with LEMS were treated with FIRDAPSE, including 102 patients treated for more than 6 months, 77 patients treated for more than 12 months, and 53 patients treated for more than 18 months.
Study 1 was a double-blind, placebo-controlled, randomized discontinuation study in adults with LEMS. Following an initial open-label run-in phase (up to 90 days), patients were randomized to either continue FIRDAPSE treatment or transition to placebo for a 14-day double-blind phase. Following nal assessments, patients were allowed to resume
FIRDAPSE treatment for up to 2 years (open-label, long-term safety phase of the study).
During the open-label run-in phase of Study 1, 53 patients received FIRDAPSE for an average of 81 days at an average daily dosage of 50.5 mg/day. The average patient age was 52.1 years and 66% were female. There were 42 patients who had no prior exposure to FIRDAPSE at the initiation of this study.
Table 1 shows adverse reactions with an incidence of 5% or greater occurring in the 42 LEMS patients newly initiated on treatment with FIRDAPSE during the run-in phase of the study.
Table 1. Adverse Reactions in ≥5% of LEMS Patients Newly Treated with FIRDAPSE in Study 1
There are no data on the developmental risk associated with the use of FIRDAPSE in pregnant women. In animal studies, administration of amifampridine phosphate to rats during pregnancy and lactation resulted in developmental toxicity (increase in stillbirths and pup deaths, reduced pup weight, and delayed sexual development) at doses associated with maternal plasma drug levels lower than therapeutic drug levels (see Animal Data). In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. The background risk of major birth defects and miscarriage for the indicated population is unknown.
*Includes paresthesia, oral paresthesia, oral hypoesthesia
**Includes elevated alanine aminotransferase (ALT), aspartate aminotransferase (AST), lactate dehydrogenase (LDH), and gamma-glutamyl transferase (GGT)
In the overall population treated in Study 1 (n=53), including the double-blind phase and the 2-year open-label long-term safety phase, additional adverse reactions occurring in at least 5% of the patients included: dyspnea, urinary tract infection, gastroesophageal re ux, insomnia, peripheral edema, pyrexia, viral infection, blood creatine phosphokinase increase, depression, erythema, hypercholesterolemia, and in uenza. These patients received an average daily dosage of 66 mg of FIRDAPSE.
The concomitant use of FIRDAPSE and drugs that lower seizure threshold may lead to an increased risk of seizures. The decision to administer FIRDAPSE concomitantly with drugs that lower the seizure threshold should be carefully considered in light of the severity of the associated risks.
The concomitant use of FIRDAPSE and drugs with cholinergic effects (e.g., direct or indirect cholinesterase inhibitors) may increase the cholinergic effects of FIRDAPSE and of those drugs and increase the risk of adverse reactions.
There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to FIRDAPSE during pregnancy. Physicians are encouraged to enroll pregnant patients, or pregnant women may register themselves in the registry by calling 855-212-5856 (toll-free), using the Fax number 877-867-1874 (toll-free), by contacting the Pregnancy Coordinating Center at rdapsepregnancyregistry@ubc.com or by visiting the study website at www. rdapsepregnancystudy.com.
Oral administration of amifampridine phosphate (0, 7.5, 22.5, or 75 mg/kg/day) to female rats prior to and during mating and continuing throughout organogenesis produced no adverse effects on embryofetal development. Plasma amifampridine exposure (AUC) at the highest dose tested is approximately 7 times that in humans at the maximum recommended human dose (MRHD) of 80 mg amifampridine/day. Oral administration of amifampridine phosphate (0, 9, 30, or 57 mg/kg/day) to pregnant rabbits throughout organogenesis produced no adverse effects on embryofetal development. The highest dose tested is approximately 7 times the MRHD (80 mg/day amifampridine) on a body surface area (mg/m2) basis. Oral administration of amifampridine phosphate (0, 7.5, 22.5, or 75 mg/kg/day) to female rats throughout pregnancy and lactation resulted in an increase in stillbirths and pup deaths, reduced pup weight, and delayed sexual development in female pups at the mid and high doses tested. The no-effect dose (7.5 mg/kg/day amifampridine phosphate) for adverse developmental effects is associated with a plasma amifampridine exposure (AUC) less than that in humans at the MRHD.
There are no data on the presence of FIRDAPSE in human milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health bene ts of breastfeeding should be considered along with the mother’s clinical need for FIRDAPSE and any potential adverse effects on the breastfed infant from FIRDAPSE or from the underlying maternal condition.
In lactating rat, amifampridine was excreted in milk and reached levels similar to those in maternal plasma.
Safety and effectiveness in pediatric patients have not been established.
Clinical studies of FIRDAPSE did not include suf cient numbers of subjects aged 65 and over (19 of 63 patients in Studies 1 and 2) to determine whether they respond differently from younger subjects. Other reported clinical experience has not identi ed differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, re ecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.
Renal clearance is an elimination pathway for amifampridine and the inactive metabolite, 3-N-acetyl amifampridine, and exposure of amifampridine is higher in subjects with renal impairment. Therefore, in patients with renal impairment, FIRDAPSE should be initiated at the lowest recommended starting dosage (15 mg/day), and patients should be closely monitored for adverse reactions. Consider dosage modi cation or discontinuation of FIRDAPSE for patients with renal impairment as needed based on clinical
effect and tolerability. The safety, ef cacy, and pharmacokinetics of amifampridine have not been studied in patients with end-stage renal disease (CLcr <15 mL/min or patients requiring dialysis).
No dosage recommendation for FIRDAPSE can be made for patients with end-stage renal disease.
The effects of FIRDAPSE have not been studied in patients with hepatic impairment. FIRDAPSE is extensively metabolized by N-acetyltransferase 2 (NAT2) and hepatic impairment may cause an increase in exposure. Therefore, initiate FIRDAPSE in patients with any degree of hepatic impairment at the lowest recommended starting dosage (15 mg/day) and monitor for adverse reactions.
Consider dosage modi cation or discontinuation of FIRDAPSE for patients with hepatic impairment as needed based on clinical effect and tolerability.
Exposure of FIRDAPSE is increased in patients who are N-acetyltransferase 2 (NAT2) poor metabolizers.
Therefore, initiate FIRDAPSE in patients who are known NAT2 poor metabolizers at the lowest recommended starting dosage (15 mg/day) and monitor for adverse reactions. Consider dosage modi cation of FIRDAPSE for patients who are known NAT2 poor metabolizers as needed based on clinical effect and tolerability.
Advise the patient and/or caregiver to read the FDA-approved patient labeling (Medication Guide).
Inform patients that FIRDAPSE can cause seizures, and to notify their healthcare provider if they experience a seizure.
Instruct patients to inform their healthcare provider if they have signs or symptoms of hypersensitivity, and to seek emergency help if symptoms of anaphylaxis occur.
Instruct patients to take FIRDAPSE exactly as prescribed. Patients should carefully follow the dose escalation schedule provided by their healthcare provider to safely achieve the therapeutic dosage.
Inform patients that the tablets may be divided in half at the score, if needed. Instruct patients not to take a double dose to make up for a missed dose.
Instruct patients to notify their healthcare provider prior to starting any new medication, including over-the-counter drugs.
Instruct patients that if they are pregnant or plan to become pregnant while taking FIRDAPSE they should inform their healthcare provider. Advise patients that there is a pregnancy registry that monitors pregnancy outcomes in women exposed to FIRDAPSE during pregnancy and encourage them to enroll if they become pregnant while taking FIRDAPSE [see Use in Speci c Populations (8.1) of full Prescribing Information].
Advise patients to store FIRDAPSE at 68°F to 77°F (20°C to 25°C).
Distributed by Catalyst Pharmaceuticals, Inc., Coral Gables, FL 33134.
FIRDAPSE® is a registered trademark of SERB. Catalyst and the Catalyst logo are trademarks of Catalyst Pharmaceuticals, Inc.
© 2022 Catalyst Pharmaceuticals, Inc. All Rights Reserved.
8:00 a.m. –12:00 p.m.
APP1: Advanced Practice Provider Pre-conference: General Session 4
Location: Caesars Palace - Octavius 9-11
Learning Objectives: Participants should become familiar with basic neuroanatomy and issues related to localizing the lesion in neurology with clinical correlations; the application of EMG and EEG in clinical practice, including utilization and interpretation; and the application and interpretation of the most-utilized imaging strategies in clinical neurology including CT and MRI. This program will not be available within the virtual platform.
8:10 a.m.–9:15 a.m.
» Neurology Fundamentals: Basic Neuroanatomy, Localizing the Lesion, and Clinical Correlations
Jaffar Khan, MD, FAAN, Atlanta, GA 9:25 a.m.–10:05 a.m.
» Neurodiagnostics: EMG
Ruple S. Laughlin, MD, FAAN, Rochester, MN 10:05 a.m.–10:45 a.m.
» Neurodiagnostics: EEG
Joseph I. Sirven, MD, FAAN, Jacksonville, FL 11:00 a.m.–12:00 p.m.
» Neuroimaging
Ryan Hakimi, DO, Greenville, SC 1:00 p.m. –5:30 p.m.
APP2 : Advanced Practice Provider Pre-conference: Update and Overview
Location: Caesars Palace - Octavius 9-11
Learning Objectives: Participants should learn the optimal evaluation and management of patients with cognitive impairment/dementia, epilepsy, movement disorders, headache, and critical care. This program will not be available within the virtual platform.
Lecture/Faculty:
1:00 p.m.–1:45 p.m.
» Differentiating the Dementias
Debbie Gunter, NP, Duluth, GA
1:45 p.m.–2:30 p.m.
» Epilepsy
Joseph I. Sirven, MD, FAAN, Jacksonville, FL
Lucretia Long, CNP, Columbus, OH
2:45 p.m.–3:30 p.m.
» Movement Disorders
Shannon Anderson, PA, Portland, OR
3:30 p.m.–4:15 p.m.
» Headache
Calli Leighann Cook, DNP, FNP-C, FAANP, Atlanta, GA
Jessica Ailani, MD, FAAN, McLean, VA
4:30 p.m.–5:15 p.m.
Emmaculate Mmboga Fields, NP, Oklahoma City, OK
Ryan Hakimi, DO, Greenville, SC
1:00 p.m. –5:30 p.m.
Pre-conference: Techniques and Skills
Location: Caesars Palace - Octavius 15-16
CME 4.5
Learning Objectives: Participants should gain familiarity with some of the neurology procedures available, including deep brain stimulation programming, botulinum toxin use in treatment of migraine, nerve blocks in selected headache disorders, lumbar puncture, and concussion evaluation and management; be able to explain their indications and rationale for use; and develop a general understanding of the performance of the procedure. Attendees will not develop proficiency or procedural certification during these sessions. This program will not be available within the virtual platform.
1:00 p.m.–1:45 p.m.
» Deep Brain Stimulation
Shannon Anderson, PA, Portland, OR
1:45 p.m.–2:30 p.m.
» Botulinum Toxin Use in Treatment of Migraine
Calli Leighann Cook, DNP, FNP-C, FAANP, Atlanta, GA
2:45 p.m.–3:30 p.m.
» Nerve Blocks—Headache
Calli Leighann Cook, DNP, FNP-C, FAANP, Atlanta, GA
3:30 p.m.–4:15 p.m.
» Lumbar Punctures
Terri Milburn, Atlanta, GA
4:30 p.m.–5:15 p.m.
Glynnis Zieman, MD, Phoenix, AZ
Information is accurate as of October 7, 2022, and is subject to change. Unless otherwise indicated, programs are available in Las Vegas and online.
11:40 a.m. –1:00 p.m.
Location: Caesars Palace - Octavius 13-14
8:00 a.m. –5:15 p.m.
Location: Caesars Palace - Octavius 19-21
12:00 p.m.–12:30 p.m.
» Special Populations: Pediatric TBI
Sean C. Rose, MD, Columbus, OH
1:15 p.m.–1:45 p.m.
»
8
Learning Objectives: Participants should be able to describe emerging concepts regarding the pathophysiology of concussion and diagnostic biomarkers; institute clinically useful diagnostic tests when indicated; provide state-of-theart management of concussed athletes and individuals, including those with persistent symptoms; implement safe and appropriate return to play, school, work, and life decisions; and educate athletes, non-health care professionals, and other health care practitioners on key issues related to concussion. This program will not be available within the virtual platform.
Lecture/Faculty:
8:05 a.m.–8:35 a.m.
» Updated Guidelines for Acute Concussion for the General Neurologist
Erik John Beltran, MD, Lincolnshire, IL
8:40 a.m.–9:10 a.m.
» Post-concussion Syndrome: A Word About Pathophysiology and How to Clinically Approach a Patient Who Isn’t Improving
Jose H. Posas, MD, FAAN, New Orleans, LA
9:10 a.m.–9:40 a.m.
» Post-traumatic Headache
Juliana VanderPluym, MD, Scottsdale, AZ
9:40 a.m.–10:10 a.m.
» Post-traumatic Orthostatic Tachycardia/ Autonomic Dysfunction
Rachel Pearson, MD, Orange, CA
10:10 a.m.–10:50 a.m.
» Relationship of TBI to Neurodegenerative Disease
Michael S. Jaffee, MD, FAAN, Gainesville, FL
11:00 a.m.–11:30 a.m.
» Special Populations: Military
Walter S. Dunn, MD, PhD, Los Angeles, CA
11:30 a.m.–12:00 p.m.
» Special Populations: Domestic Abuse/IPV Glynnis Zieman, MD, Phoenix, AZ
Breakout Session: Key Elements on the Physical Exam
Erik John Beltran, MD, Lincolnshire, IL
Jose H. Posas, MD, FAAN, New Orleans, LA
1:15 p.m.–1:45 p.m.
»
Breakout Session: Sports Neurology as a Career/What Is Sports Neurology
Nicole Dorothy Reams, MD, FAAN, Glenview, IL
Glynnis Zieman, MD, Phoenix, AZ
Sean C. Rose, MD, Columbus, OH
2:00 p.m.–2:30 p.m.
» Sleep
Michael S. Jaffee, MD, FAAN, Gainesville, FL
2:30 p.m.–3:00 p.m.
» Mental Health Interventions for Persistent Symptoms After Concussion
Aliyah Ryan Snyder, PhD, Gainesville, FL
3:10 p.m.–3:35 p.m.
» Big Data: ENIGMA
Kevin Bickart, MD, PhD, Los Angeles, CA
3:35 p.m.–4:00 p.m.
» Big Data: CARE4Kids
Gerard A. Gioia, MD, Rockville, MD
4:10 p.m.–5:00 p.m.
» Closing Keynote: When Is It NOT a Concussion: Exploring the Differential Diagnosis
Sofia Chambers, Los Angeles, CA
5:30 p.m. –6:30 p.m.
Location: Octavius 13-14
7:30 a.m. –7:45 a.m.
Location: Courses - Online Only
Learning Objectives: Check out each days “Live from Las Vegas” kickoff—only available in the virtual platform! Get a preview of the day ahead with can’t-miss highlights from Regional Conferences Subcommittee Chair Jonathan Graff-Radford, MD. Find out how to make the most of your time during the virtual conference! This program is available only within the virtual platform. To view, visit AAN.com/VirtualFC
7:30 a.m.–7:45 a.m.
» Friday’s Live from Las Vegas Virtual Kickoff
Vijay K. Ramanan, MD, PhD, Rochester, MN
Casey S.W. Albin, MD, Atlanta, GA
Jonathan Graff-Radford, MD, Rochester, MN
8:00 a.m. –9:30 a.m.
Location: Caesars Palace - Octavius 9-11
Learning Objectives: Epilepsy: Participants should learn about the new anti-seizure medicines currently available; understand the cardiac risks associated with the use of anti-seizure medicines; describe the role of cellphone video in diagnosing epilepsy; and explain the purpose of seizure forecasting. Headache: Participants should increase knowledge to properly diagnosis primary headache disorders including migraine and cluster headache, and to be able to identify red flags that suggest secondary headache; acquire clinical knowledge to develop a multidisciplinary care plan, including screening for comorbidities, and developing pharmacological and non-pharmacological treatment plans; increase knowledge of clinical factors for the identification of patients and phenotypes to optimize outcomes; and increase competence in the selection of an appropriate CGRP-targeted therapy for the management of migraine.
8:00 a.m.–8:45 a.m.
» Epilepsy
Jacqueline French, MD, FAAN, New York, NY 8:45 a.m.–9:30 a.m.
» Headache
Teshamae Monteith, MD, FAAN, Miami, FL
Location: Caesars Palace - Octavius 19-21
CME 1.5
Learning Objectives: Participants should become familiar with the developments in the diagnosis of autoimmune Myasthenia Gravis, currently available therapeutics, and potential new therapies in the pipeline with novel mechanisms of action.
8:00 a.m.–8:05 a.m.
» Myasthenia Gravis
Srikanth Muppidi, MD, FAAN, Stanford, CA
8:05 a.m.–8:45 a.m.
»
Myasthenia Gravis and Traditional Therapies
Shaida Khan, DO, Dallas, TX
8:45 a.m.–9:25 a.m.
»
Myasthenia Gravis and Newer Therapies
(Complement and FcRN)
Srikanth Muppidi, MD, FAAN, Stanford, CA
8:00 a.m. –9:30 a.m.
Location: Caesars Palace - Octavius 15-16
CME 1.5
Learning Objectives: “Why do I need to know about coding?” It’s not why we went into medicine. However, it can make or break your professional practice. Let’s talk about how you can use coding to demonstrate the quality of our practice, enhance reimbursement, and improve your quality of life.
8:05 a.m.–9:15 a.m.
» Keeping Up with CMS: Staying Current with CPT Changes and Increasing Revenue
Korwyn Williams, MD, PhD, FAAN, Phoenix, AZ
Jose M. Rocha, MHL, Medley, FL
8:00 a.m. –9:30 a.m.
Location: Caesars Palace - Octavius 17-18
CME 1.5
Learning Objectives: To lead others most effectively, you first need to know how to lead yourself. Where are you going, why are you going there, and what impact do you want to make along
Information is accurate as of October 7, 2022, and is subject to change. Unless otherwise indicated, programs are available in Las Vegas and online.
the way? The answers to these questions form the foundation to the purpose, the mission, the vision, and the goals that guide your leadership approach and support your own and others’ engagement and success. Join us for this session to continue to build your leadership foundation. Attendees will leave the program with an initial draft of a leadership purpose statement. This program will not be available within the virtual platform.
8:05 a.m.–8:20 a.m.
» Personal Mission and Vision
Mona Bahouth, MD, Baltimore, MD
8:20 a.m.–9:30 a.m.
» Interactive Group Work and Discussion
Robin Stubblefield, MA, ACC, Executive coach, Vitalize Consulting, LLC
Mona Bahouth, MD, Baltimore, MD
9:30 a.m. –10:00 a.m.
ELA1: The Intersection of Wellness, Diversity, and Inclusion
Location: Caesars Palace - Octavius 24-25
Learning Objectives: Participants should be able to discuss the common goals shared between Wellness and Diversity/Equity Committees. Please bring some best practice examples as we share some experiences from our wellness centers.
9:30 a.m.–10:00 a.m.
» The Intersection of Wellness, Diversity, and Inclusion
Madeline A. Chadehumbe, MD, Voorhees, NJ
9:30 a.m. –10:00 a.m.
Location: Caesars Palace - Exhibit HallOctavius 12-14
10:00 a.m. –11:30 a.m.
Location: Caesars Palace - Octavius 9-11
emerging therapies for status epilepticus. Neuro Ethics: Participants should become familiar with AAN Ethics, Law and Humanities Committee position statements; review ethical considerations in neuropalliative care and lawful physicianhastened death; review ethical considerations in the diagnosis and management of disorders of consciousness; and review ethical considerations in the determination of death by neurologic criteria. Lecture/Faculty:
10:00 a.m.–10:45 a.m.
» Neurology Emergencies
Casey S.W. Albin, MD, Atlanta, GA
10:45 a.m.–11:30 a.m.
» Neuro Ethics
Ariane Lewis, MD, FAAN, New York, NY
10:00 a.m. –11:30 a.m.
Location: Caesars Palace - Octavius 15-16
Learning Objectives: With continued downward pressure on reimbursements for personallyperformed services and escalating practice expenses, creating new and diverse sources of revenue is critical to the financial success of a neurology practice. Presenters will provide insights and practical tools in exploring revenue diversification strategies through an expanded services model to include infusion, diagnostic imaging, clinical research, sleep, and EEG. Join this session to see which ancillary service(s) may benefit your practice and considerations of each to include financial modeling and performing a risk assessment.
10:05 a.m.–10:40 a.m.
»
Ancillary Services in the Neurology Practice
Jeffrey B. English, MD, Atlanta, GA
10:40 a.m.–11:15 a.m.
» Adding Services Lines
Amy Rene Knighton, Savannah, GA
1.5
Learning Objectives: Neurology Emergencies: Participants should understand the implications of TELSTAR and TTM2 on the management of patients with hypoxic ischemic brain injuries; become familiar with impactful changes in the 2022 AHA/ASA guidelines for management of intracranial hemorrhage; and recognize novel and
Location: Caesars Palace - Octavius 17-18
CME 1.5
Learning Objectives: Participants should become familiar with the concepts of management and leadership and what it takes to successfully navigate and influence in the health care landscape today. Neurology leaders will share personal stories, real life examples, and relevant anecdotes that demonstrate that developing as a manager and leader is a lifelong journey and that leadership can occur both formally and informally. Panelists will highlight shifts they have experienced and opportunities and challenges they see on the horizon of neurology and health care. This program will not be available within the virtual platform.
Lecture/Faculty:
10:00 a.m.–10:05 a.m.
» Welcome
James C. Stevens, MD, FAAN, Fort Wayne, IN 10:05 a.m.–10:20 a.m.
» Observations on Management and Leadership
James C. Stevens, MD, FAAN, Fort Wayne, IN 10:20 a.m.–11:00 a.m.
» Panel Discussion
David A. Evans, MBA, Dallas, TX
Hope O’Brien, MD, FAAN, MBA, Cincinnati, OH
James C. Stevens, MD, FAAN, Fort Wayne, IN
Brad C. Klein, MD, MBA, FAAN, Abington, PA
Robin Stubblefield, MA, ACC, Executive Coach, Vitalize Consulting, LLC
11:00 a.m.–11:30 a.m.
» Questions and Answers
David A. Evans, MBA, Dallas, TX
Hope O’Brien, MD, FAAN, MBA, Cincinnati, OH
James C. Stevens, MD, FAAN, Fort Wayne, IN
Brad C. Klein, MD, MBA, FAAN, Abington, PA
Robin Stubblefield, MA, ACC, Executive Coach, Vitalize Consulting, LLC
Location: Caesars Palace - Octavius 19-21
CME 1.5
Learning Objectives: Presenters will highlight issues most critical to practicing neurologists, including clinical applications of basic and translational research and innovative technical developments.
10:00 a.m.–10:35 a.m.
» Determinants of Disparate Disability Accumulation in Black, Hispanic, and White Patients with Multiple Sclerosis
Christopher Michael Orlando, MD, MPH, Houston, TX
10:45 a.m.–11:20 a.m.
» Functional Neurologic Symptoms in the Time of COVID-19: Learning From Tic-like Behaviors
Davide Martino, MD, PhD, Calgary, AB, Canada
11:30 a.m. –1:00 p.m.
Location: Caesars Palace - Exhibit HallOctavius 12-14
11:45 a.m. –12:45 p.m.
Location: Caesars Palace - Octavius 24-25
Learning Objectives: Participants should become familiar with the diagnosis, classification, and treatment of common and uncommon epilepsy presentations.
11:45 a.m.–12:45 p.m.
» Curbside Consults: Epilepsy
Jacqueline French, MD, FAAN, New York, NY
Information is accurate as of October 7, 2022, and is subject to change. Unless otherwise indicated, programs are available in Las Vegas and online.
Location: Courses - Online Only
Learning Objectives: Participants should understand the basic pharmacological concepts relevant to the clinical practice of neurology as well as an approach to medication selection for patients with epilepsy. This program is available only within the virtual platform. To view, visit AAN.com/VirtualFC
Lecture/Faculty:
11:45 a.m.–12:45 p.m.
» Epilepsy
Hernan Nicolas Lemus Esquivel, MD, Brookline, MA
11:45 a.m. –12:45 p.m.
Location: Caesars Palace - Octavius 6
Learning Objectives: Join advanced practice providers (APPs) and other professionals to discuss issues and solutions affecting APPs in neurology.
Lecture/Faculty:
11:45 a.m.–12:45 p.m.
» Advanced Practice Provider Networking Session
Shannon Anderson, PA, Portland, OR
11:45 a.m. –12:45 p.m.
Location: Caesars Palace - Octavius 15-16
Learning Objectives: What is your practice’s biggest pain point? Come network with your peers to brainstorm solutions, identify best practices, and discuss other hot topics related to the business of neurology.
Lecture/Faculty:
11:45 a.m.–12:45 p.m.
» Business Administrator Networking Session
Amy Rene Knighton, Savannah, GA
Location: Caesars Palace - Octavius 9-11
CME 1.5
Participants will review classification and treatment of immune-mediated demyelinating neuropathies and discuss advancements in genebased therapeutics in neuromuscular disorders.
Adolescent/Child Neurology: This lecture should improve the confidence of adult practitioners in caring for children with neurodevelopmental differences and complex congenital disorders with increased survival into adulthood.
1:00 p.m.–1:45 p.m.
» Neuromuscular Disease
Leo Hong-Li Wang, MD, PhD, FAAN, Seattle, WA
1:45 p.m.–2:30 p.m.
» Adolescent/Child Neurology for the Adult Neurologist
Madeline A. Chadehumbe, MD, Voorhees, NJ
Location: Caesars Palace - Octavius 19-21
CME 1.5
Learning Objectives: Participants should be able to describe clinical presentation of NMOSD; discuss diagnostic criteria for NMOSD; compare and contrast clinical features of NMOSD with common diseases that mimic NMOSD; be familiar with the imaging characteristics of NMOSD; and discuss approved treatment options for NMOSD.
1:00 p.m.–2:30 p.m.
» Neuromyelitis Optica Spectrum Disorders
Amy T. Waldman, MD, Philadelphia, PA
Location: Caesars Palace - Octavius 15-16
Learning Objectives: Telehealth is now an indelible part of our health care landscape. Presenters will discuss current clinical, technological, and practice management aspects of virtual care delivery models and help participants anticipate future developments. This course will explore how a practice’s telehealth services can provide high-quality patient care and meet your business needs and goals. Presenters will examine how to adapt the different telehealth models to your practice’s individual needs and how to scale for growth.
1:05 p.m.–1:40 p.m.
» Current and Future Trends in Telehealth
Benjamin R. Kummer, MD, New York, NY
1:40 p.m.–2:15 p.m.
» Solutions, Policies, and Procedures for Practicing Telehealth Post-pandemic
Amy Martens, MBA, Nashville, TN
1:00 p.m. –2:30 p.m.
Location: Caesars Palace - Octavius 17-18
1:10 p.m.–2:00 p.m.
David M. Greer, MD, FAAN, Boston, MA
Thabele M. Leslie-Mazwi, MD, Seattle, WA
Salvador Cruz-Flores, MD, FAAN, El Paso, TX
Jana Pettit, MBA, Seattle, WA
Cathy A. Sila, MD, FAAN, Cleveland, OH
2:00 p.m.–2:30 p.m.
David M. Greer, MD, FAAN, Boston, MA
Thabele M. Leslie-Mazwi, MD, Seattle, WA
Salvador Cruz-Flores, MD, FAAN, El Paso, TX
Jana Pettit, MBA, Seattle, WA
Cathy A. Sila, MD, FAAN, Cleveland, OH
Location: Caesars Palace - Exhibit HallOctavius 12-14
Location: Caesars Palace - Octavius 9-11
Learning Objectives: Participants should gain tools and frameworks for effective decision making, moving strategies forward, and accomplishing goals. Learn how leaders in health care organizations and neurology departments build consensus among stakeholders and their team by developing strategic plan documents. Participants will learn how to develop short-term and long-term goals, execute goals on a specific timeline, and the common traps of strategic thinking. A panel of neurology leaders will discuss concrete solutions and real-life scenarios, including what has worked and what hasn’t worked for them. This program will not be available within the virtual platform.
1:00 p.m.–1:10 p.m.
David M. Greer, MD, FAAN, Boston, MA
Learning Objectives: Dementia: Participants should be able to describe contemporary clinical criteria for Alzheimer’s disease (AD) and its subtypes; explain the current use of imaging biomarkers for the diagnosis of AD; understand the rationale for cerebrospinal fluid testing in the diagnosis of dementia; outline the potential future use of blood tests in the diagnosis of AD; understand the difference between causal and risk genes for AD; list the major genetic causes of familial frontotemporal dementia and their associated pathologies and imaging findings; list the core diagnostic criteria for Lewy body dementias; understand the major modifiable risk factors for dementia; and name the currently licensed medications for Alzheimer’s disease and appreciate the major approaches being tested in clinical trials.
3:00 p.m.–3:45 p.m.
» Dementia
Jonathan Schott, BSc, MD, MRCP, London, United Kingdom
3:45 p.m.–4:30 p.m.
Michelle Fabian, MD, FAAN, New York, NY
Information is accurate as of October 7, 2022, and is subject to change. Unless otherwise indicated, programs are available in Las Vegas and online.
Location: Caesars Palace - Octavius 19-21
Learning Objectives: Participants will be able to describe new treatments for the acute and preventive treatment of migraine, evaluate and apply new research findings for idiopathic intracranial hypertension, and estimate the likelihood of detecting a spinal CSF leak based on brain MRI findings.
3:00 p.m.–3:35 p.m.
» Hot Topics in Headache Clinic
Jessica Ailani, MD, FAAN, McLean, VA
3:45 p.m.–4:20 p.m
» IIH and SIH: New Insights in Biology and Therapy
Deborah I. Friedman, MD, MPH, FAAN, Dallas, TX
3:00 p.m. –4:30 p.m.
C11: Practice Management 4: HR/ Staffing
Location: Caesars Palace - Octavius 15-16
Learning Objectives: Following the height of the COVID-19 pandemic, we face continued inequities in health care and an employment crisis impacting all medical professionals. It is time to rethink our approach to recruitment and to focus our time and effort on retention strategies. Presenters will discuss methods to improve recruitment, retention, training, and diversity in the health care workforce. This course will emphasize the need for an organizational culture that values open communication, teamwork, and inclusion, aimed at retaining talent through engagement and encouraging teams to reach their greatest potential. Presenters will share ideas and strategies to assist neurology practices in building the best possible workforce of physicians, APPs, and staff.
3:05 p.m.–4:15 p.m.
Lee Williams, Amherst, NY
Andrew J. Gordon, MD, Lake Barrington, IL
Location: Caesars Palace - Octavius 17-18
Learning Objectives: Do you see a change that is needed but no one is listening? There is no question that project management and communication plans are important to the change process, but people are what actually make or break a change initiative. Join us in this session to actively engage in understanding the human side of change and learning how to apply key elements of communication during change. Increase awareness about your own and others potential triggers and pitfalls of change and how constructive communication can help move others from a place of resistance to a place of empowerment. Participants will have the opportunity to discuss real life scenarios/ interactions and apply key concepts within discussions. This program will not be available within the virtual platform.
3:00 p.m.–3:20 p.m.
» The Impact of Communication on Change
Jennifer Bickel, MD, FAAN, Tampa, FL
Robin Stubblefield, MA, ACC, Executive Coach, Vitalize Consulting, LLC
3:20 p.m.–4:30 p.m.
» Interactive Small Group Sessions with Attendees and Discussion
Jennifer Bickel, MD, FAAN, Tampa, FL
Robin Stubblefield, MA, ACC, Executive Coach, Vitalize Consulting, LLC
Location: Caesars Palace - Exhibit HallOctavius 12-14
28
4:30 p.m. –5:30 p.m.
Location: Caesars Palace - Octavius 24-25
Learning Objectives: A fan favorite, this program will present two expert clinical neurologists’ insights into the performance and interpretation of the neurologic examination.
4:30 p.m.–5:30 p.m.
Nancy J. Newman, MD, FAAN, Atlanta, GA
Amy A. Pruitt, MD, FAAN, Philadelphia, PA
4:45 p.m. –5:45 p.m.
Location: Courses - Online Only
Learning Objectives: Aprender sobre avances recientes en el diagnóstico y seguimiento de los desordenes del movimiento. Aprender sobre avances en el manejo de desordenes de movimiento. Aprender los resultados de ensayos clínicos publicados en 2022. Aprender sobre avances recientes en el diagnóstico y seguimiento de los trastornos neurológicos funcionales.
Reconocer que el proceso se explicación del diagnóstico es el componente más importante para la terapia. Aprender recientes avances en el manejo de trastornos neurológicos funcionales. This program is available only within the virtual platform. To view, visit AAN.com/VirtualFC
Lecture/Faculty:
4:45 p.m.–5:15 p.m.
» Movement Disorders
Andres Felipe Deik Acosta Madiedo, MD, FAAN, Philadelphia, PA
5:15 p.m.–5:35 p.m.
» Functional Neurologic Disorders
Alberto J. Espay, MD, FAAN, Cincinnati, OH
Information is accurate as of October 7, 2022, and is subject to change. Unless otherwise indicated, programs are available in Las Vegas and online.
Location: Courses - Online Only
Learning Objectives: Check out each days “Live from Las Vegas” kickoff—only available in the virtual platform! Get a preview of the day ahead with can’t-miss highlights from Regional Conferences Subcommittee Chair Jonathan Graff-Radford, MD. Find out how to make the most of your time during the virtual conference! This program is available only within the virtual platform. To view, visit AAN.com/VirtualFC
7:30 a.m.–7:45 a.m.
» Saturday’s Live from Las Vegas Virtual Kickoff
Vijay K. Ramanan, MD, PhD, Rochester, MN Jonathan Graff-Radford, MD, Rochester, MN
8:00 a.m. –9:30 a.m.
Location: Caesars Palace - Octavius 9-11
Learning Objectives: Neuro-ophthalmology: Participants should be able to differentiate among the many pathophysiologies that can affect the optic nerve; understand the contribution of new technologies and clinical trial results to the field of neuro-ophthalmology; and appreciate that the neuro-ophthalmologic examination and findings are windows into understanding the brain and neurology. Neurotoxicology: Participants should have a clear understanding of how to diagnose and treat neurological disorders that may accompany illicit drug use and heavy metal toxicity; recognize the neurotoxicity associated with newer pharmaceuticals like chimeric antigen receptor T-cell therapy and therapy with immune checkpoint inhibitors; be familiar with toxidromes like serotonin syndrome, neuroleptic malignant syndrome, posterior reversible encephalopathy syndrome, and reversible cerebral vasoconstriction syndrome; and recognize neurotoxicity associated with cyanide, carbon monoxide, and certain bacterial and animal toxins.
8:00 a.m.–8:45 a.m.
» Neuro-ophthalmology
Nancy J. Newman, MD, FAAN, Atlanta, GA
8:45 a.m.–9:30 a.m.
» Neurotoxicology
Neeraj Kumar, MD, Rochester, MN
8:00 a.m. –9:30 a.m.
Location: Caesars Palace - Octavius 15-16
CME 1.5
Learning Objectives: Participants should learn about the increasing presence of Learning Health Systems (LHS), its role, and implications for the future of care delivery, documentation, and reimbursement. An LHS is a health system in which internal data and experience are systematically integrated with external evidence, and that knowledge is put into practice. As a result, patients get higher quality, safer, and more efficient care.
8:05 a.m.–9:15 a.m.
» Learning Health Care Systems
Jeffrey R. Buchhalter, MD, FAAN, Phoenix, AZ
Sarah Duffy, Boston, MA
Location: Caesars Palace - Octavius 19-21
Location: Caesars Palace - Octavius 24-25
Learning Objectives: Presenters will discuss recent applications of deep learning and artificial intelligence (AI) within the neurology clinical practice, highlighting recent successes as well as existing challenges. Clinicians and neuroscientists will review the basics of deep learning and discuss examples of current and future applications in stroke, epilepsy/sleep, neuroimaging/neurooncology, and others.
8:00 a.m.–8:05 a.m.
» AI and Machine Learning Tools in Neurology Clinics: Opportunities and Barriers
Antonio M. P. Omuro, MD, New Haven, CT
8:05 a.m.–8:25 a.m.
» The State of Machine Learning Technologies in Neurology
Sunil Sheth, MD, Houston, TX
8:25 a.m.–8:45 a.m.
» AI/Deep Learning Applications in Neuroimaging and Neuro-oncology
Mariam Aboian, MD, PhD, Woodbridge, CT
8:45 a.m.–9:05 a.m.
» AI/ Deep Learning Applications in Electrophysiology, Epilepsy and Sleep
Daniel Goldenholz, MD, PhD, Boston, MA
9:05 a.m.–9:20 a.m.
» AI/ Deep Learning Applications in Stroke
Sunil Sheth, MD, Houston, TX
Learning Objectives: In this pandemic world, people are considering job changes more than ever before. Join us for an authentic discussion about the emotional roller coaster of changing careers. Learn from your peers about why they changed their careers, how they did it and how it all turned out.
9:30 a.m.–10:30 a.m.
» Fireside Chat: Thinking of Changing Careers
Jennifer Bickel, MD, FAAN, Tampa, FL
9:30 a.m. –10:00 a.m.
Location: Caesars Palace - Exhibit HallOctavius 12-14
10:00 a.m. –11:30 a.m.
Location: Caesars Palace - Octavius 9-11
CME 1.5
Learning Objectives: Participants will review most common types of primary intracranial tumors in adults; update molecular drivers of tumor behavior and prognosis; and highlight the newest treatment strategies for brain tumors.
Lecture/Faculty:
10:00 a.m.–10:45 a.m.
» Infectious Disease
Michael R. Wilson, MD, FAAN, San Francisco, CA
10:45 a.m.–11:30 a.m.
» Neuro-oncology
Justin T. Jordan, MD, MPH, FAAN, Boston, MA
Information is accurate as of October 7, 2022, and is subject to change. Unless otherwise indicated, programs are available in Las Vegas and online.
Location: Caesars Palace - Octavius 19-21
1.5
Learning Objectives: Participants should become familiar with the differential diagnosis of neurologic manifestations of rheumatological, systemic inflammatory, and other autoimmune diseases; be able to identify common phenotypes associated with neurologic organ system involvement of rheumatological syndromes; learn ways of distinguishing neuro-rheumatological diagnoses from other neuroinflammatory disorders; and develop practical approaches to treatment, care coordination, and health maintenance for neuro-rheumatological conditions.
10:05 a.m.–10:30 a.m.
» Neurological Manifestations of Rheumatological Disease & Systemic Autoimmunity
Amanda Lee Piquet, MD, Aurora, CO 10:30 a.m.–11:00 a.m.
» Neurosarcoidosis
Siddharama Pawate, MD, Nashville, TN 11:00 a.m.–11:25 p.m.
» Real-world Clinical Cases in Neurorheumatology
Amanda Lee Piquet, MD, Aurora, CO
Siddharama Pawate, MD, Nashville, TN
Location: Caesars Palace - Octavius 15-16
Learning Objectives: Value-based payment models have significantly penetrated the health care market, with major payers spending upwards of 50 percent for care delivered in a value-based model. Even in fee-for-service, payers are using sophisticated data analytics that effectively assesses value. This session will provide practical insights on improving and demonstrating your value in the true clinical sense and the eyes of payers. We will start with capturing and refining what you are already doing and expand into how process refinement, technology, and teams can help efficiently identify, manage, document, and ultimately improve outcomes for at-risk populations.
10:05 a.m.–11:15 a.m.
» What is Value-based Care? Opportunities and Ideas
Aiesha Ahmed, MD, FAAN, Grand Rapids, MI
Joseph V. Fritz, PhD, Amherst, NY
Location: Caesars Palace - Exhibit HallOctavius 12-14
11:45 a.m. –12:45 p.m.
Location: Caesars Palace - Octavius 24-25
Learning Objectives: Participants should recognize principles guided by subspecialty memory clinic experience in the evaluation of cognitive disorders; apply concepts of diagnosis and management to example cases from the speaker’s clinical practice; and engage in active discussions about real-world case descriptions provided by audience members.
11:45 a.m.–12:45 p.m.
» Curbside Consults: Dementia
Vijay K. Ramanan, MD, PhD, Rochester, MN
Location: Courses - Online Only
Learning Objectives: Participants should understand the basic pharmacological concepts relevant to the clinical practice of neurology as well as an approach to medication selection for patients with headache. This program is available only within the virtual platform. To view, visit AAN.com/VirtualFC
Lecture/Faculty:
11:45 a.m.–12:45 p.m.
» Headache
Gustavo A. Patino, MD, PhD, Rochester, MI
1:00 p.m. –2:30 p.m.
Location: Caesars Palace - Octavius 9-11
Learning Objectives: Participants should be able to increase and refresh their knowledge of core topics in neurology through presentation of common and not-so-common clinical problems. The two core topics include peripheral nerve and motor neuron disorders, and neuro-infectious diseases. Participants should also learn to work through difficult clinical presentations both logically and successfully. To utilize the audience response system, please visit AAN.cnf.io. ABPN
Approval: The American Board of Psychiatry and Neurology has reviewed the course Continuum®
Test Your Knowledge: A Multiple-choice Review 1 and has approved this activity as part of a comprehensive Self-assessment (SA) activity, which is mandated by the ABMS as a necessary component of Continuing Certification.
Lecture/Faculty:
1:00 p.m.–1:45 p.m.
» Peripheral Nerve and Motor Neuron Disorders
A. Gordon Smith, MD, FAAN, Richmond, VA 1:45 p.m.–2:30 p.m.
» Neuro-infectious Diseases
Aaron L. Berkowitz, MD, PhD, FAAN, San Francisco, CA
Location: Caesars Palace - Octavius 19-21
Learning Objectives: Participants should be able to describe LGBTQI terminology and health disparities, identify strategies for LGBTQI-inclusive neurologic care, and apply this knowledge in case-based scenarios to improve neurologic health equity for LGBTQI people.
Lecture/Faculty:
1:00 p.m.–1:30 p.m.
Starane Anthony Shepherd, MD, Atlanta, GA
1:30 p.m.–2:00 p.m.
Nicole Rosendale, MD, San Francisco, CA
1:00 p.m. –2:30 p.m.
Location: Caesars Palace - Octavius 15-16
Learning Objectives: Administrative burdens on providers have escalated over the past two decades and make up a significant portion of their work. This course will highlight best practices in managing prior authorization (PA) requirements by payers including the utilization of 3rd party service providers to ease the PA burden. Attendees will also learn how to navigate their state’s step therapy laws or advocate for them in states where none exist.
1:05 p.m.–2:15 p.m.
» Practice and Innovation
Jose M. Rocha, MHL, Medley, FL
David A. Evans, MBA, Dallas, TX
Information is accurate as of October 7, 2022, and is subject to change. Unless otherwise indicated, programs are available in Las Vegas and online.
Location: Caesars Palace - Octavius 17-18
Learning Objectives: Participants should become familiar with the indications of peripheral cranial nerve blocks, trigger point injections, and onabotulinumtoxin A in the treatment of headache disorders, and also gain experience with these different injection techniques during the hands-on portion.The hands-on portion of this program will not be available in the virtual platform.
1:05 p.m.–1:25 p.m.
» Onabotulinumtoxin A
Brinder Vij, MD, Cincinnati, OH
1:25 p.m.–1:45 p.m.
» Nerve Blocks - GONB, LONB, SONB, STNB, SPG, Trigger Point Injections
Cynthia Emilie Armand, MD, Bronx, NY
1:45 p.m.–2:05 p.m.
» Surgical Intervention for Migraine
Paul G. Mathew, MD, FAAN, FAHS, Braintree, MA
2:05 p.m.–2:25 p.m.
» Invasive Treatments of Migraine in Pediatrics and Adolescents
Marielle Kabbouche Samaha, MD, FAHS, FAAN, Cincinnati, OH
2:25 p.m.–2:45 p.m.
» Neuromodulation for Migraine Acute Treatment
Deena Kuruvilla, MD, Southport, CT
2:45 p.m.–3:05 p.m.
» Neuromodulation for Migraine Prevention
Michael J. Marmura, MD, FAAN, Philadelphia, PA
3:20 p.m.–5:00 p.m.
» Breakout Rotations
Hope O’Brien, MD, FAAN, MBA, Cincinnati, OH
Cynthia Emilie Armand, MD, Bronx, NY
Brinder Vij, MD, Cincinnati, OH
Deena Kuruvilla, MD, Southport, CT
Marielle Kabbouche Samaha, MD, FAHS, FAAN, Cincinnati, OH
Paul G. Mathew, MD, FAAN, FAHS, Braintree, MA
Michael J. Marmura, MD, FAAN, Philadelphia, PA
Location: Caesars Palace - Octavius Foyer
3:00 p.m. –4:30 p.m.
Location: Caesars Palace - Octavius 9-11
Learning Objectives: Participants should be able to increase and refresh their knowledge of core topics in neurology through presentation of common and not-so-common clinical problems. The two core topics include neurology of pregnancy and dementia. Participants should also learn to work through difficult clinical presentations both logically and successfully. To utilize the audience response system, please visit AAN.cnf.io. ABPN Approval: The American Board of Psychiatry and Neurology has reviewed the course Continuum® Test Your Knowledge: A Multiple-choice Review 2 and has approved this activity as part of a comprehensive Self-assessment (SA) activity, which is mandated by the ABMS as a necessary component of Continuing Certification.
Lecture/Faculty:
3:00 p.m.–3:45 p.m.
» Neurology of Pregnancy
Melissa Lynn Rayhill, MD, FAAN, Buffalo, NY
3:45 p.m.–4:30 p.m.
» Dementia
Gregory S. Day, MD, MSc, FAAN, Jacksonville, FL
Location: Caesars Palace - Octavius 15-16
CME 1.5
Location: Caesars Palace - Octavius 19-21
Learning Objectives: Neurology physicianowned private practices continue to decrease in number, which makes it harder for practices to stay in business. To keep a practice thriving, it must stand out amongst the many other systemowned practices. Presenters will moderate active discussions on unique ways to enhance your practice. Leading examples include leveraging individual strengths, highlighting subspecialty clinical areas, integrating clinical trials and other forms of research, fostering specific populations through innovative approaches, partnering with academic medical centers and incorporating learners, and more. Come join the discussion and share.
3:05 p.m.–3:40 p.m.
» Building a Comprehensive Subspecialty Clinic Within a Private Practice Model
Augusto A. Miravalle, MD, FAAN, Fort Collins, CO
3:40 p.m.–4:15 p.m.
» Productivity—Subspecialty, Maximizing Strengths, and Mitigating Weaknesses
Sonya Knight, DO, FAAN, Blue Bell, PA
Learning Objectives: Participants should learn the latest, cutting-edge translational research related to clinical issues of importance. Three outstanding speakers provide summaries of their recent research findings and describe the clinical implications of the results.
3:00 p.m.–3:30 p.m.
» Therapeutically Targeting Senescent Cells to Treat Age-related Diseases
Miranda E. Orr, PhD, Winston-Salem, NC
3:30 p.m.–4:00 p.m.
» Viruses and Neurologic Autoimmunity
Michael R. Wilson, MD, FAAN, San Francisco, CA
4:00 p.m.–4:30 p.m.
» Glymphatic System Dysfunction: A Unifying Feature in Neurodegeneration
Humberto Mestre, MD, PhD, Philadelphia, PA
Information is accurate as of October 7, 2022, and is subject to change. Unless otherwise indicated, programs are available in Las Vegas and online.
Location: Caesars Palace - Octavius 9-11
CME 1.5
Learning Objectives: Movement Disorders: Participants should learn about recent advances in the diagnosis of movement disorders; learn about recent advances in the management of movement disorders; and learn the results of recentlypublished clinical trials. Sleep: Participants should be able to list the common sleep disorders, list examples of risks associated with the common sleep disorders, and describe clinical presentations of the common sleep disorders.
7:30 a.m.–8:15 a.m.
Andres Felipe Deik Acosta Madiedo, MD, FAAN, Philadelphia, PA
8:15 a.m.–9:00 a.m.
» Sleep
Rachel Marie E. Salas, MD, MEd, FAAN, Baltimore, MD
7:30 a.m. –9:00 a.m.
Location: Caesars Palace - Octavius 19-21
Learning Objectives: This course is designed to help clinicians when presented with a patient with a rapidly progressive dementia (RPD) or related syndrome to understand the evaluation pathway and how it differs from that of a typical or slowly progressive dementia syndrome; develop and apply a diagnostic algorithm for various testing, including ruling out potentially reversible or curable etiologies; and provide practical framework for diagnosis of autoimmune encephalitis.
7:30 a.m.–8:15 a.m.
» RPD Summary and Prion Disease
Michael D. Geschwind, MD, PhD, FAAN, San Francisco, CA
8:15 a.m.–8:45 a.m.
Jeffrey Marc Gelfand, MD, MAS, FAAN, San Francisco, CA
Location: Caesars Palace - Octavius 9-11
CME 1.5
Learning Objectives: Learning objectives for this program are still being developed. Please continue to check AAN.com/Fall for further information.
9:30 a.m.–10:15 a.m.
» Cerebrovascular Disease
Nicole Beaton Sur, MD, Miami, FL
10:15 a.m.–11:00 a.m.
» Neurocritical Care
Avni Kapadia, MD, Shenandoah, TX
9:30 a.m. –11:00 a.m.
Location: Caesars Palace - Octavius 19-21
CME 1.5
Learning Objectives: Participants should be able to recognize different treatment strategies for relapsing multiple sclerosis (MS) when initiating and sequencing DMTs; discuss rationale for considering early highly effective and escalation therapeutic approaches: benefits, risks, and what is unknown; review real-world evidence using observational studies to support each approach; identify ongoing clinical trials assessing early treatment strategies for relapsing MS; and examine case-based scenarios that highlight different DMT approaches, including benefits and pitfalls.
9:35 a.m.–10:15 a.m.
» Treatment Strategies for Multiple Sclerosis: What We Know and What We Don’t Know
Carrie Michelle Hersh, DO, MSc, FAAN, Las Vegas, NV
10:15 a.m.–10:50 a.m.
» Treatment Strategies for Multiple Sclerosis: Case-based Scenarios
Le Hua, MD, FAAN, Las Vegas, NV
14 15
MANAGEPD.com
Explore MANAGEPD.com & MYPD-CARE.com:
Clinician & Patient Tools for Timely Treatment of Advance Parkinson’s Disease. Visit the AbbVie Medical Affairs website at www.MANAGEPD.com
AbbVie’s mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women’s health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com
abbvie.com
AbbVie’s mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women’s health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com
AbbVie’s mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key
Information is accurate as of October 7, 2022, and is subject to change.
therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women’s health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com
Acorda Therapeutics is a biopharmaceutical company that markets two products, INBRIJA® (levodopa inhalation powder) and AMPYRA ® (dalfampridine) Extended Release Tablets. www.acorda.com
Alexion is a global biopharmaceutical company with the mission of transforming the lives of people affected by rare diseases by continuously innovating and creating meaningful value in all that we do. Headquartered in Boston, Massachusetts, Alexion has offices around the globe and serves patients in more than 50 countries.
Amneal Pharmaceuticals LLC is an integrated pharmaceutical company powered by a robust U.S. generics business and a growing branded business. Our Specialty Pharma business delivers products that meet important medical needs in central nervous system disorders and other therapeutic categories. We are focused on delivering outcomes, making quality medicines more accessible and more affordable, and providing solutions for tomorrow’s health challenges. We make healthy possible.
Amylyx is a Cambridge-based pharmaceutical company dedicated to the development of therapeutics for the treatment of neurodegenerative disorders. Guided by our core values, we incorporate unconventional approaches through strong partnerships with industry leaders, scientists, doctors and organizations. We work collaboratively across everything we do to positively impact the lives of patients and their families.
argenx is a global immunology company developing antibody-based medicines for patients suffering from severe autoimmune diseases and cancer. By translating immunology breakthroughs into innovative drug candidates, argenx is building a world-class portfolio of first-in-class antibodies in both early and late clinical-stages of development.
Atrium Health, one of the nation’s leading and most innovative health care organizations, provides a full spectrum of health care and wellness programs throughout North Carolina, South Carolina and Georgia. Its diverse network of care locations includes academic medical centers, hospitals, freestanding emergency departments, physician practices, surgical and rehabilitation centers, home health agencies, nursing homes and behavioral health centers, as well as hospice and palliative care services. Atrium Health works to enhance the overall health and wellbeing of its communities through high quality patient care, education and research programs, and numerous collaborative partnerships and initiatives.
Banner Life Sciences is committed to advancing human health through scientific innovation. We are a uniquely innovative and entrepreneurial specialty pharmaceutical company. We identify unmet clinical needs for patients, and then leverage our proprietary formulation expertise and technologies to create unique solutions that not only help people to live healthy, happy lives, but also offer significant commercial advantages and valuable IP protection. Our in-house capabilities cover all the essential new product functions such as product development, clinical research, and regulatory affairs, and commercialization so we’re able to execute an end-to-end, turnkey process for creating exciting new products.
Baylor Scott & White Health is transforming health care for the Better, so that our patients and health plan members receive the high-value care they deserve when and where they need it. Our team of over 47,000 employees across more than 1,000 access points is committed to the well-being of every individual, family and community we serve. Through innovation, education and care delivery, we strive to provide an exceptional customer experience, while working to make health care more convenient and more affordable.
Billings Clinic is Montana’s largest independent health care system serving Montana, Wyoming and the western Dakotas. A not-for-profit organization led by a physician CEO, Billings Clinic is governed by a board of community members, nurses and physicians. Billings Clinic is an integrated multispecialty group practice with a 304-bed hospital and Level II trauma center. Nationally recognized for clinical quality, Billings Clinic is Magnet® designated for nursing excellence and is a member of the Mayo Clinic Care Network.
Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb , visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube, Facebook and Instagram.
The company’s first to market wrist-worn neuromodulation device, Cala Trio™ therapy, delivers electrical stimulation from the affected hand to the brain providing meaningful, temporary tremor reduction. Cala Trio therapy is delivered in 40-minute sessions calibrated to each patient’s individual tremor. Patients choose when and how often they will utilize therapy. Cala Trio therapy is noninvasive, FDA cleared, safe and effective and available only through a health care providers prescription.
Catalyst Pharmaceuticals is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing and commercializing novel high-quality medicines for patients living with rare diseases. With exceptional patient focus, Catalyst is committed to developing a robust pipeline of cutting-edge, first- or best-in-class medicines for other rare diseases. To learn more, please visit our website at www.catalystpharma.com
Information is accurate as of October 7, 2022, and is subject to change.
Located in the heart of the technology district in Milford, OH, Consolidated Neuro Supply, Inc. is a leading provider of health care products used to diagnose neurological disorders and monitor critical neurological structures during high-risk surgical procedures. Product offerings include EMG needle electrodes, subdermal needle electrodes, pedicle screw and direct nerve stimulators, and disposable EEG electrodes.
Neurology DosedDaily delivers one clinically relevant and evidence-based question to your inbox each day. In just one click you’ll learn something important every day while earning 24 AMA PRA Category 1 Credit™ that are approved for ABPN® Self-assessment Credit each year.
Edward-Elmhurst Health is one of the larger integrated health systems in Illinois. The system was created by the merger of Edward Hospital and Elmhurst Memorial Health care in 2013. Comprised of three hospitals – Edward Hospital, Elmhurst Hospital and Linden Oaks Behavioral Health
Edward-Elmhurst has: Annual revenues of more than $1 billion More than 50 outpatient locations across a service area of 1.7 million residents in the west and southwest suburbs of Chicago Nearly 7,700 employees and 1,700 volunteers More than 1,900 physicians on staff (98 percent are board certified) Nearly 100 medical and surgical specialties and subspecialties
Considered the founder of the industry, Genentech, now a member of the Roche Group, has been delivering on the promise of biotechnology for over 35 years. At Genentech, we use human genetic information to discover, develop, manufacture and commercialize medicines to treat patients with serious or life-threatening medical conditions. Today, we are among the world’s leading biotech companies, with multiple products on the market and a promising development pipeline.
Considered the founder of the industry, Genentech, now a member of the Roche Group, has been delivering on the promise of biotechnology for over 35 years. At Genentech, we use human genetic information to discover, develop, manufacture and commercialize medicines to treat patients with serious or life-threatening medical conditions. Today, we are among the world’s leading biotech companies, with multiple products on the market and a promising development pipeline.
Horizon is focused on researching, developing and commercializing medicines that address critical needs for people impacted by rare and rheumatic diseases. Our pipeline is purposeful: we apply scientific expertise and courage to bring clinically meaningful therapies to patients. We believe science and compassion must work together to transform lives.
Health care Partners Nevada, a leading network of health care providers and clinics in southern Nevada, has joined Intermountain Health care. Together, the two organizations will provide Nevada, Utah and Idaho with a stronger, more comprehensive regional health system. Our mission is: Helping people live the healthiest lives possible we are building an environment where physicians and employees can deliver the best in health care. And it’s realizing each employee or volunteer is vital to the healing process, because we can only achieve the extraordinary together. Intermountain is viewed as a leader in transforming health care through high quality and sustainable costs.
KabaFusion is a pharmacist-owned, patient focused team of professionals with over 35 years of experience in home infusion and speciality infusion and specialty infusion therapy. We are dedicated to working proactively with our patients, health care practitioners and payers to provide comprehensive support before, during and after treatment, and are recognized for our excellence in out-patient care and administration of IVIG, SCIG and acute therapies nationwide.
You can make a difference here in Montana. Billings and Bozeman are located in the magnificent Rocky Mountains with extraordinary outdoor recreation minutes from home. These friendly college communities have great schools, diverse restaurants and abundant activities for all ages. Four seasons of sunshine!
• Outpatient Neurology in Billings or Bozeman
• Neurohospitalist in Billings at our tertiary referral center
• Epileptology in Billings – EMU in development
• Primary Stroke Center
• EEG and long-term video monitoring
• Opportunity to teach with IM Residency
• J-1 visa candidates welcome
• 501c3 nonprofit organization
Contact: Billings Clinic Physician Recruitment
E-mail: physicianrecruiter@billingsclinic.org
• Magnet® Recognized for Nursing Excellence
• Montana ranked as “Top 10 Best States to Work for Doctors” –Wallethub
• Billings & Bozeman named in “Top 100 Best Places to Live in the US” – Livability
Learn more and watch our physician video: billingsclinicphysicians.com
Information is accurate as of October 7, 2022, and is subject to change.
Kaiser Permanente is passionate in our commitment to improving the nation’s health care system. Through our leadership in the use of advanced technology, our creation of innovative solutions and our influence on health policy and reform efforts, we are shaping the future of health care both nationally and abroad.
McKesson helps neurology providers run profitable, independent businesses by clearing the path for them to focus on patient care. We offer an impactful portfolio of solutions that makes practice management more manageable by increasing efficiency, productivity, and profitability for specialty providers. Our Onmark Group Purchasing Organization (GPO) helps providers maximize their purchasing power, while our support services go above and beyond the essentials of pharmaceutical distribution. We take a highly-collaborative “all in” approach to understanding each practice’s unique needs. This tailored approach informs the business insights, strategies, and resources we offer, including regulatory guidance, advocacy, and full-service management options for physicianowned specialty practices. Intrafusion by McKesson is full-service infusion management that clears the path for independent, community-based specialty providers to care for their patients while growing a successful, high-quality infusion center. Our “all in” approach combined with proven results and a comprehensive portfolio of solutions ensure your infusion center operates productively, efficiently and profitably. Our broad portfolio of services is unparalleled, as is our commitment to supporting each provider’s ability to deliver better patient care and outcomes. That’s the McKesson difference. Ask us how we can help: mckesson.com/specialty
We are the largest health care system in western South Dakota. Headquartered in Rapid City our system consists of 5 hospitals, 24 clinics and employs nearly 5000 physicians & caregivers. Our family friendly community is located in the foothills of the beautiful Black Hills which boasts a myriad of outdoor activities including hiking, camping, boating fishing & hunting.
Specialists of North Texas is looking for the next great surgeon to join our team. Your practice would include 90% elective spine. Your earning potential would easily be in the 90th percentile. You could have a broad array of cases. OR set up with Styker, Brain Lab, Aesculap, 3D C-arms, and more. Commute is less than 10 minutes. Call is 1 in 4 at a 325 bed Level II trauma center. EPIC EHR. Service area includes almost 300,000 people, great schools, a safe community, close to international airports. No state income tax. We’d love to have you stop by our booth to learn more.
NeuroNet GPO is a group purchasing organization focused on serving the needs of outpatient clinical practices and their ancillary services. GPO members partner with practices nationwide to leverage purchase power, resulting in discounted pricing on drugs and supplies. Members also gain access to valuable information and resources, which helps maximize operating performance.
Northeast Georgia Physicians Group (NGPG), one of the largest multi-specialty groups in Georgia, brings together more than 600+ talented physicians and advanced practitioners representing 30 specialties at over 70 locations. NGPG is affiliated with Northeast Georgia Health System (NGHS), which serves more than 1,200,000 people in more than 19 counties across the region. As part of NGHS, patients of NGPG have a direct connection to Northeast Georgia Medical Center’s four hospital campuses in Gainesville, Braselton, Lumpkin County and Barrow.
novartis.com
Novartis Pharmaceuticals
Largest privately owned plasma products manufacturer.
PatientPoint® is the patient engagement platform more providers trust. From patient acquisition to in-office and hospital engagement to remote care, our innovative, tech-enabled solutions deliver highly relevant, personalized health experiences across the entire patient journey. More than 140k health care providers and 500 hospitals trust PatientPoint to help them increase practice efficiencies, enhance the patient experience and improve outcomes. See how we can do the same for you.
Physicians’ Practice Enhancement, LLC is committed to the highest level of patient, hospital and physician satisfaction. As a physician-led organization, we recognize that our success is dependent on the professional satisfaction and success of our physicians and providers. At PPE, our family of clinical providers is the heart of our organization. PPE works with our clinical providers to identify long term professional goals and provide the necessary tools to fulfill these goals. In addition to professional development, PPE offers leadership training, especially for those seeking clinical administrative goals. We reinforce this family values and emphasis on education and training through our firm commitment to promote from within. PPE’s diverse corporate team of clinical directors, practice managers, client services, payroll, human resources, and provider enrollment offer “back-office” support, such as 24/7 scheduling services, allowing you to focus more time on patient care.
PTC is a science-driven, global biopharmaceutical company focused on the discovery, development and commercialization of clinically-differentiated medicines that provide benefits to patients with rare disorders.
RosmanSearch is a Neurosurgery, Neurology and APP recruitment firm. We place quality providers with quality practices nationwide. We are the only search firm with dedicated teams specializing in neuroscience. Our mission is to be the best, the most expert, and the one that is known for quality—every time!
Information is accurate as of October 7, 2022, and is subject to change.
Trinity Life Sciences is a trusted strategic commercialization partner, providing evidencebased solutions for the life sciences. With 25 years of experience, Trinity is committed to revolutionizing the commercial model by providing exceptional levels of service, powerful tools and data-driven insights. Trinity’s range of products and solutions includes industry-leading benchmarking solutions, powered by TGaS Advisors. To learn more about how Trinity is elevating life sciences and driving evidence to action, visit trinitylifesciences.com
UCB, Brussels, Belgium is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. Follow us on Twitter: @ UCB_news.
WellStar Health System is a non-profit health system serving more than one million people in metro Atlanta, GA. We are the largest health system in the southeast and the only one in the area to be selected as a member of the Mayo Clinic Care Network. Our patient-centered culture is the ideal setting for physicians seeking an integrated, collaborative environment in which to thrive. WellStar is the premier choice for patients and physicians. As we grow, we are seeking physicians to join our team.
Wolters Kluwer Health is a global provider of information, business intelligence and point-ofcare solutions for the health care industry . Brands include Lippincott Williams & Wilkins, a leading international publisher of medical books, electronic media and journals and the official publisher of American Academy of Neurology. We proudly offer specialized publications and software for physicians, nurses, students and clinicians. Please visit our booth to browse our comprehensive product line.
Zeto is changing the way Routine EEG is done at hospitals. ‘Fast, convenient, medical-grade EEG’, is what we do. Our product is the first FDA cleared dry electrode EEG headset and software platform. Patent pending, zero-prep and easy to wear headset with electrodes placed as per the 10-20 EEG system backed by a cloud platform that offers instant upload, tools for analysis and live viewing from any location. Zeto also makes EEG available to facilities that currently do not have access to it.
Visit AAN.com/Fall for complete information on our COVID-19 safety protocols. Following are highlights and reminders for how we’re working to keep everyone safe.
Choose a green, yellow, or red lanyard to communicate your comfort level:
Green: High fives and handshakes are okay with frequent hand washing.
Yellow: Elbows only. Still being cautious.
Red: No contact. Maintain distance where possible.
The AAN expects all attendees to be respectful of fellow attendees’ preferences.
Masks are required indoors during the meeting for all Fall Conference attendees, except when actively eating, drinking, or presenting. A limited supply of KN95 masks will be available near registration.
Information about COVID-19 testing locations is available at nvcovidfighter.org/find-test
The following are a selection of guidelines for AAN conferences. Complete conference guidelines are available at AAN.com/ConfGuidelines.
AAN Fall Conference/Pre-conference registrants must agree to conference guidelines during the registration process.
Unless specified, these guidelines apply to all AAN conference formats. In addition to the below guidelines, participation in a live or virtual AAN meeting is subject to AAN’s Privacy Policy (AAN.com/PrivacyPolicy). All individuals engaged in any live or virtual meeting are subject to the Code of Conduct at AAN.com/Conduct, unless otherwise specifically noted. Use of the website and virtual program site(s) is subject to AAN’s Terms of Use (AAN.com/TermsofUse).
These conference policies are subject to change without notice, at AAN’s discretion. Any changes will be reflected on AAN.com/ConfGuidelines.
The American Academy of Neurology Institute (AANI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The American Academy of Neurology Institute (AANI), a subsidiary of the AAN, designates this live activity for a maximum of (*) AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. *See individual program descriptions starting on page 10 for the maximum number of credits per program.
The AAN is committed to intentional actions to be a fully inclusive, deliberately diverse, and anti-racist organization that respects and values our membership, our staff, and the communities we serve. We actively promote equity and social justice in neurology and the neurosciences. As part of this commitment, the AAN is working to ensure we provide a conference environment and educational programming that is fully inclusive, deliberately diverse, and anti-racist. If you have questions about these efforts, identify areas for improvement, or have concerns regarding attendee or staff behavior, please contact Member Services at (800) 879-1960, memberservices@aan.com, or conference staff at registration@aan.com.
The AAN expects all meeting participants, including attendees, members, speakers, staff, contractors, vendors, and exhibitors, to behave respectfully, responsibly, and professionally towards each other, and to abide by the AAN’s Meetings Anti-harassment Policy (AAN.com/Anti-harassment), during the conference. The AAN is committed to providing a conference environment that is free from all forms of discrimination and harassment. Violations of this policy may be reported to Member Services at (800) 8791960, memberservices@aan.com, or to conference staff at registration@aan.com
The American Academy of Neurology (AAN) encourages all AAN conference attendees to share their experience on social media using the official conference hashtag, #AANFC When doing so, please adhere to the following AAN Meetings Social Media Policies:
• Photography and screenshots of presentations are permitted for personal use only. Photography or screenshots for commercial use are strictly prohibited.
• Do not disrupt fellow attendees.
• Do not post any information or other material protected by copyright without the permission of the copyright owner.
• Do not post confidential or identifiable patient information.
• Do not post any material that is defamatory, abusive, profane, threatening, offensive, illegal, or violates any third party’s rights.
• Videography, including live streaming, is strictly prohibited regardless of intended use.
• Usage of the AAN logo or an AAN conference logo on social media is prohibited.
The AAN has the right to ask any AAN conference attendee to remove a social post or to stop taking photos or recording video at any time.
